Baxter International Inc.

Ohmeda Pharmaceutical Products Division Inc.

Ralph A Lessor

Leonid A Rozov

Keith Ramig

Linas V Kudzma

Ralph V Rudzinski

Satish K Pejaver

Navneet Puri

Raul Trillo

Satish Pejaver

A container for liquid inhalation anesthetics, more particularly, an aluminum container that is suitable for storing halogenated inhalation anesthetics is described.

Container for inhalation anesthetic

Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.

Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics

Provided is a process of obtaining 1,1,1,3,3,3-hexafluoro-2-propanol ('HFIP') from a composition comprising an HFIP hydrolyzable precursor. The HFIP hydrolyzable precursor is a compound, other than sevoflurane itself, that has an intact 1,1,1,3,3,3-hexafluoroisopropoxy moiety[(CF)CHO&#x2014;], and contains one or more moieties susceptible to acidic hydrolysis, such that HFIP is released upon such treatment. The process is useful, among other things, for recovering HFIP from waste streams associated with the synthesis of the inhalation anesthetic, fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether ('sevoflurane'). The process includes heating the composition with a strong protic acid to a temperature effective to hydrolyze at least some of the HFIP hydrolyzable precursor to HFIP, and then isolating the HFIP from the heated composition.

Process for recovery of 1,1,1,3,3,3-hexafluoroisopropanol from the waste stream of sevoflurane synthesis

Provided is a method for the preparation of desflurane wherein isoflurane is reacted with 0.7-1.2 mol. % of antimony pentachloride and 1.3-2.2 molar equivalents of hydrogen fluoride. Typically, the method is conducted by addition of hydrogen fluoride to a mixture of isoflurane and antimony pentachloride. After the addition of hydrogen fluoride is completed, the reaction is preferably maintained at temperatures of about 9-18&deg; C. for about 6 to 7 hours, before being quenched.

Preparation of desflurane

The invention provides a process for purifying methyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether, comprising: passing a composition comprising methyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether and dimethyl ether through an evaporation zone; evaporating dimethyl ether by passing a gas stream through the composition; and removing the gas comprising dimethyl ether from the composition.

Process for removal of dimethyl ether in the synthesis of sevoflurane

A method of preparing fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether (sevoflurane) and structurally related monofluoromethyl ethers in which the monochloromethyl ether precursor thereof is reacted with a sterically hindered tertiary amine hydrofluoride salt.

Method of preparing monofluoromethyl ethers

This invention pertains to methods for preparing 5-aroyl-1,2-dihydro-3H-pyrrolo-[1,2-a]pyrrole-1-carboxylic acids represented by formula (I): ##STR1## In a first embodiment, the method comprises the sequential steps of cyclizing, via a free radical ring closure reaction, and hydrolyzing a compound represented by formula (IV): ##STR2## wherein R.sub.1 is lower alkyl. In a second embodiment, the method comprises the sequential steps of hydrolyzing and decarboxylating a compound represented by formula (VIII): ##STR3##

Growing community of inventors

New Providence, NJ, United States of America

Ralph A Lessor